Skip to main navigation

About
our medicine
science & pipeline
Patients
healthcare professionals
Investors
Careers

About
our medicine
science & pipeline
Patients
healthcare professionals
Investors
Careers

News Releases

Year

July 7, 2026

PDF Version

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2026

PDF Version

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

June 1, 2026

PDF Version

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 27, 2026

PDF Version

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 6, 2026

PDF Version

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 29, 2026

PDF Version

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

April 1, 2026

PDF Version

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2026

PDF Version

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 4, 2026

PDF Version

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

March 2, 2026

PDF Version

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

quick links

Quick Links

About
Patients
Investors
Careers

contact

X4 Pharmaceuticals
61 North Beacon Street
4th Floor
Boston, MA 02134 Phone: 857.529.8300

© 2026 X4 Pharmaceuticals, Inc. All rights reserved.

Live - Footer

Terms of Use | Privacy | Compliance and Ethics